冠状动脉疾病
医学
生物标志物
基质金属蛋白酶
内科学
病理生理学
急性冠脉综合征
疾病
冠状动脉粥样硬化
心脏病学
易损斑块
金属蛋白酶组织抑制剂
生物信息学
心肌梗塞
生物
生物化学
作者
Yuval Konstantino,Tu T. Nguyen,Robert Wołk,Robert J. Aiello,Steven G. Terra,David A. Fryburg
出处
期刊:Biomarkers
[Informa]
日期:2009-03-01
卷期号:14 (2): 118-129
被引量:38
标识
DOI:10.1080/13547500902765140
摘要
Matrix metalloproteinase (MMP)-9, a member of the MMP superfamily is consistently implicated in the pathophysiology of atherosclerosis and plaque rupture, the most common mechanism responsible for acute coronary syndrome (ACS).To summarize the role of MMP-9 in atherosclerosis and its potential implications in assessment and treatment of coronary artery disease (CAD).We reviewed the PubMed database for relevant data regarding the role of MMP-9 in the pathophysiology of atherosclerosis. In the light of these data, we postulate potential implications of MMP-9 in the management and treatment of CAD.Existing data strongly support the role of MMP-9 in plaque destabilization and rupture. Based on the current knowledge, MMP-9 can potentially serve as a diagnostic biomarker in ACS and a prognostic biomarker in ACS and chronic CAD patients. MMP-9 is reduced by therapies that are associated with favourable outcome in atherosclerosis and thus may serve as a surrogate biomarker of treatment efficacy. However, large morbidity and mortality trials are still required to confirm that MMP-9 reduction is associated with improved outcome independent of the traditional risk factors (i.e. low-density lipoprotein cholesterol). Given its role in plaque rupture, inhibition of MMP-9 may promote plaque stabilization and consequently reduce cardiovascular events. Yet, the efficacy and safety of MMPs inhibitors should be first studied in preclinical models of atherosclerosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI